Patents by Inventor Carolyn Diane Dzierba

Carolyn Diane Dzierba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20240109888
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: July 6, 2023
    Publication date: April 4, 2024
    Inventors: Guanglin Luo, Jie Chen, Carolyn Diane Dzierba, David B. Frennesson, Junqing Guo, Amy C. Hart, Xirui Hu, Michael E. Mertzman, Matthew Reiser Patton, Jianliang Shi, Steven H. Spergel, Brian Lee Venables, Yong-Jin Wu, Zili Xiao, Michael G. Yang
  • Triazolopyridinyl compounds as kinase inhibitors
    Patent number: 11767322
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: September 26, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Jie Chen, Carolyn Diane Dzierba, David B. Frennesson, Junqing Guo, Amy C. Hart, Xirui Hu, Michael C. Mertzman, Matthew Reiser Patton, Jianliang Shi, Steven H. Spergel, Brian Lee Venables, Yong-Jin Wu, Zili Xiao, Michael G. Yang
  • Aminopyrrolotriazines as kinase inhibitors
    Patent number: 11618753
    Abstract: The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: April 4, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Carolyn Diane Dzierba, Hua Gong, Jason M. Guernon, Junqing Guo, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Brian Lee Venables, Carolyn A. Weigelt, Yong-Jin Wu, Zhizhen Barbara Zheng, Sing-Yuen Sit, Jie Chen
  • 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1)
    Publication number: 20220380335
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: September 12, 2019
    Publication date: December 1, 2022
    Inventors: Junqing Guo, Jie Chen, Carolyn Diane Dzierba, Amy C. Hart, Guanglin Luo, John E. Macor, Willian J. Pitts, Sing-Yuen Sit
  • INDAZOLE CARBOXAMIDES AS KINASE INHIBITORS
    Publication number: 20220380355
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: October 2, 2020
    Publication date: December 1, 2022
    Inventors: Jie Chen, Carolyn Diane Dzierba, Junqing Goo, Amy C. Hart, William J. Pitts, Sing-Yuen Sit
  • AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS
    Publication number: 20220315580
    Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: December 9, 2020
    Publication date: October 6, 2022
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • Aminoimidazopyridazines as kinase inhibitors
    Patent number: 11440913
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: September 13, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael E. Mertzman, Carolyn Diane Dzierba, Jason M. Guernon, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Steven H. Spergel
  • TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20220119388
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: October 18, 2021
    Publication date: April 21, 2022
    Inventors: Guanglin Luo, Jie Chen, Carolyn Diane Dzierba, David B. Frennesson, Junqing Guo, Amy C. Hart, Xirui Hu, Michael C. Mertzman, Matthew Reiser Patton, Jianliang Shi, Steven H. Spergel, Brian Lee Venables, Yong-Jin Wu, Zili Xiao, Michael G. Yang
  • INDAZOLE CARBOXAMIDES AS KINASE INHIBITORS
    Publication number: 20210309633
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: September 12, 2019
    Publication date: October 7, 2021
    Inventors: Junqing Guo, Carolyn Diane Dzierba, Amy C. Hart, John E. Macor, William J. Pitts
  • BIARYL KINASE INHIBITORS
    Publication number: 20210277001
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: March 5, 2021
    Publication date: September 9, 2021
    Inventors: Guanglin Luo, Carolyn Diane Dzierba, John E. Macor
  • Biaryl kinase inhibitors
    Patent number: 10981910
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: April 20, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Carolyn Diane Dzierba, John E. Macor
  • Aminotriazolopyridines as kinase inhibitors
    Patent number: 10913738
    Abstract: Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: February 9, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS
    Publication number: 20200347071
    Abstract: The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.
    Type: Application
    Filed: January 24, 2019
    Publication date: November 5, 2020
    Inventors: Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Carolyn Diane Dzierba, Hua Gong, Jason M. Guernon, Junqing Guo, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Brian Lee Venables, Carolyn A. Weigelt, Yong-Jin Wu, Zhizhen Barbara Zheng, Sing-Yuen Sit, Jie Chen
  • BIARYL KINASE INHIBITORS
    Publication number: 20200317671
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: June 26, 2020
    Publication date: October 8, 2020
    Inventors: Guanglin Luo, Carolyn Diane Dzierba, John E. Macor
  • AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS
    Publication number: 20200277296
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: October 29, 2018
    Publication date: September 3, 2020
    Inventors: Michael E. Mertzman, Carolyn Diane Dzierba, Jason M. Guernon, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Steven H. Spergel
  • Biaryl kinase inhibitors
    Patent number: 10723734
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: July 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Carolyn Diane Dzierba, John E. Macor
  • Biaryl kinase inhibitors
    Patent number: 10544120
    Abstract: The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: January 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joanne J. Bronson, Ling Chen, Jonathan L. Ditta, Carolyn Diane Dzierba, Prasada Rao Jalagam, Guanglin Luo, John E. Macor, Tarun Kumar Maishal, Susheel Jethanand Nara, Ramkumar Rajamani, Ramesh Kumar Sistla, Soodamani Thangavel
  • AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS
    Publication number: 20190389859
    Abstract: Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Application
    Filed: February 12, 2018
    Publication date: December 26, 2019
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • BIARYL KINASE INHIBITORS
    Publication number: 20190367508
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: June 18, 2019
    Publication date: December 5, 2019
    Inventors: Guanglin Luo, Carolyn Diane Dzierba, John E. Macor
  • Aryl lactam kinase inhibitors
    Patent number: 10253027
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: April 9, 2019
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Joanne J. Bronson, Carolyn Diane Dzierba, John E. Macor, Susheel Jethanand Nara, Ramkumar Rajamani